Dr. Reddy's Laboratories launches generic version of Sapropterin Dihydrochloride Tablets for Oral Use in the U.S. Market

Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as "Dr. Reddy's") today announced the launch of a generic version of Sapropterin Dihydrochloride Tablets, for Oral Use.

"We are pleased to launch this generic version of Sapropterin Dihydrochloride Tablets, for Oral Use, illustrating our continued commitment to bring affordable generic medicines to market for patients," says Marc Kikuchi, Chief Executive Officer, North America Generics, Dr. Reddy's Laboratories. "At the same time, this product demonstrates that we are actively expanding the breadth of our portfolio with a treatment for a rare disease. We are pleased to provide financial support to patients by offering a co-pay card program for eligible patients, details will be available on our website."

Dr. Reddy's Sapropterin Dihydrochloride Tablets, 100 mg are available in bottle count sizes of 120.

Shares of DR.REDDY'S LABORATORIES LTD. was last trading in BSE at Rs.5113.8 as compared to the previous close of Rs. 5187.05. The total number of shares traded during the day was 53711 in over 5197 trades.

The stock hit an intraday high of Rs. 5259.4 and intraday low of 5092.95. The net turnover during the day was Rs. 276679721.

Source : Equity Bulls

Keywords